Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Other 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Breast Neoplasms 2Overweight 1Obesity 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Trastuzumab 260Paclitaxel 216Cyclophosphamide 173Docetaxel 146Letrozole 126Fulvestrant 121Capecitabine 121Doxorubicin 111Carboplatin 98Bevacizumab 90exemestane 88Anastrozole 85Tamoxifen 77Lapatinib 77pembrolizumab 68Albumin-Bound Paclitaxel 67pertuzumab 62palbociclib 60Taxes 59Gemcitabine 57eribulin 48130-nm albumin-bound paclitaxel 47Radiotherapy 46Everolimus 44Ado-Trastuzumab Emtansine 43Vinorelbine 39ixabepilone 32Epirubicin 30Cisplatin 30pegfilgrastim 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Naltrexone × Breast × Clear all
NCT04499950 2025-03-06

A-NEW

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
53 enrolled 14 charts
BreastOther

Breast Neoplasms, Obesity, Overweight

NCT02137252 2021-11-16

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Lobular

NCT00379197 2017-12-28

Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
13 enrolled 4 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡